In Amgen-Sanofi Decision, High Court Sticks to Patent Law Script

Director Will Milliken was quoted in the article “In Amgen-Sanofi Decision, High Court Sticks to Patent Law Script,” published by Bloomberg Law. Will provided the following commentary on the Supreme Court affirming the Federal Circuit’s ruling that the Amgen patent claims at issue are not enabled:

“Will Milliken, co-chair of Sterne, Kessler, Goldstein & Fox PLLC’s appellate practice, said the court reiterated that patent law should be applied consistently across inventions.

“This suggests that, in the Court’s view, the same enablement analysis applies to all patents, no matter the technology—antibody patents are not special,” Milliken wrote in an email to Bloomberg Law.”